IBUDILAST AND IMMUNOMODULATORS COMBINATION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 14, 2010
app pub date -
Apr 7, 2010
filing date -
Apr 9, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention contemplates methods and compositions for treating multiple sclerosis including the administration of a PDE inhibitor and at least one immunomodulator comprising mitoxantrone, natalizumab, fingolimod, laquinimod, cladribine, dimethylfumarate or a mixture comprising synthetic polypeptide analogs of myelin basic protein, including alanine, glutamic acid, lysine, and tyrosine amino acid residues, in a therapeutically effective amount. A preferred PDE inhibitor includes ibudilast.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully